Prostaglandin Analogues for Raynaud Phenomenon in Systemic Sclerosis
Author Information
Author(s): Hana Alahmari, Hila Jazayeri, Sindhu R. Johnson
Primary Institution: King Khalid University, Toronto Scleroderma Program, University of Toronto
Hypothesis
This systematic review and meta-analysis evaluated the efficacy and tolerability of prostaglandin analogues in treating systemic sclerosis-associated Raynaud phenomenon.
Conclusion
Prostaglandin analogues are beneficial in the short term to reduce the severity of Raynaud phenomenon and are tolerable.
Supporting Evidence
- Prostaglandin analogues effectively control the symptoms of Raynaud phenomenon among people with systemic sclerosis.
- Daily oral prostaglandin reduces the odds of new ulcers by about 10% in the long term.
- Prostaglandin analogues have shared mechanisms of action that address the complexity of systemic sclerosis-associated Raynaud phenomenon.
Takeaway
This study shows that certain medications can help people with a condition that causes their fingers to turn cold and painful.
Methodology
The study systematically reviewed randomized control trials evaluating prostaglandin use in systemic sclerosis-associated Raynaud phenomenon.
Potential Biases
There is a high risk of bias in some studies due to information ambiguity.
Limitations
The study included a small number of trials and had low certainty of evidence.
Participant Demographics
The studies included adult participants classified with systemic sclerosis.
Statistical Information
P-Value
0.01
Confidence Interval
95% CI −0.99, −0.27
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website